SKIN
The Beauty Health Company [SKIN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SKIN Stock Summary
Top SKIN Correlated Resources
SKIN
Top 10 Correlated ETFs
SKIN
Top 10 Correlated Stocks
SKIN
In the News
SKIN Financial details
Company Rating
Neutral
Market Cap
451.74M
Income
-102.04M
Revenue
398M
Book val./share
0.46
Cash/share
4.06
Dividend
-
Dividend %
-
Employees
881
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-4.18
Forward P/E
-
PEG
0.12
P/S
0.92
P/B
4.12
P/C
0.8
P/FCF
34.24
Quick Ratio
4.98
Current Ratio
5.86
Debt / Equity
12.51
LT Debt / Equity
12.43
-
-
EPS (TTM)
-0.78
EPS next Y
-
EPS next Q
-
EPS this Y
-353.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
71.65%
Revenue last 5Y
19.02%
Revenue Q/Q
-0.62%
EPS Q/Q
-86.96%
-
-
-
-
SMA20
-
SMA50
33.33%
SMA100
100%
Inst Own
58.54%
Inst Trans
0.76%
ROA
-9%
ROE
-62%
ROC
-0.14%
Gross Margin
44%
Oper. Margin
-29%
Profit Margin
-22%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.35-13.9
52W High
-74.96%
52W Low
+225.5%
RSI
39
Rel Volume
0.37
Avg Volume
2.7M
Volume
1.01M
Perf Week
-14.34%
Perf Month
-9.58%
Perf Quarter
-28.3%
Perf Half Y
-36.43%
-
-
-
-
Beta
1.016
-
-
Volatility
0.13%, 0.36%
Prev Close
-5.1%
Price
3.255
Change
-1.96%
SKIN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 5.18 | 3.47 | 2.55 | 2.48 | 3.02 | |
| Net income per share | -0.05 | -0.85 | -3.67 | 0.3 | -0.76 | |
| Operating cash flow per share | 0.05 | -0.36 | -0.28 | -0.72 | 0.17 | |
| Free cash flow per share | -0.27 | -0.47 | -0.43 | -0.84 | 0.07 | |
| Cash per share | 0.23 | 0.28 | 8.83 | 3.85 | 3.97 | |
| Book value per share | -0.04 | -0.87 | 2.96 | 1.16 | 0.45 | |
| Tangible book value per share | -4.98 | -5.23 | 1.2 | 0 | -0.98 | |
| Share holders equity per share | -0.04 | -0.87 | 2.96 | 1.16 | 0.45 | |
| Interest debt per share | 6.44 | 6.93 | 7.3 | 5.19 | 5.75 | |
| Market cap | 348.36M | 387.86M | 2.47B | 1.34B | 409.53M | |
| Enterprise value | 530.83M | 594.91M | 2.3B | 1.53B | 638.79M | |
| P/E ratio | -212.67 | -13.29 | -6.58 | 30.36 | -4.09 | |
| Price to sales ratio | 2.09 | 3.26 | 9.49 | 3.67 | 1.03 | |
| POCF ratio | 201.6 | -31.19 | -86.99 | -12.6 | 18.83 | |
| PFCF ratio | -40.07 | -23.86 | -56.1 | -10.83 | 47.07 | |
| P/B Ratio | -288.37 | -12.95 | 8.16 | 7.83 | 6.9 | |
| PTB ratio | -288.37 | -12.95 | 8.16 | 7.83 | 6.9 | |
| EV to sales | 3.19 | 5 | 8.82 | 4.17 | 1.61 | |
| Enterprise value over EBITDA | 19.04 | -210.36 | -26.03 | -91.1 | -6.98 | |
| EV to operating cash flow | 307.19 | -47.84 | -80.93 | -14.32 | 29.37 | |
| EV to free cash flow | -61.06 | -36.6 | -52.19 | -12.31 | 73.42 | |
| Earnings yield | 0 | -0.08 | -0.15 | 0.03 | -0.24 | |
| Free cash flow yield | -0.02 | -0.04 | -0.02 | -0.09 | 0.02 | |
| Debt to equity | -157.1 | -7.23 | 2.43 | 4.38 | 12.51 | |
| Debt to assets | 0.84 | 0.97 | 0.6 | 0.75 | 0.8 | |
| Net debt to EBITDA | 6.55 | -73.21 | 1.95 | -10.96 | -2.51 | |
| Current ratio | 1.43 | 1.91 | 13.09 | 10.79 | 6.07 | |
| Interest coverage | 0.79 | -0.81 | -3.11 | -1.81 | -9.06 | |
| Income quality | -1.05 | 0.43 | 0.08 | -2.4 | -0.22 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | -0.01 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.16 | 0.26 | 0.38 | 0.29 | 0.33 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | |
| Intangibles to total assets | 0.7 | 0.67 | 0.15 | 0.17 | 0.2 | |
| Capex to operating cash flow | -6.03 | 0.31 | 0.55 | 0.16 | -0.6 | |
| Capex to revenue | -0.06 | -0.03 | -0.06 | -0.05 | -0.03 | |
| Capex to depreciation | -0.75 | -0.27 | -0.74 | -0.79 | -0.4 | |
| Stock based compensation to revenue | 0 | 0 | 0.05 | 0.08 | 0.06 | |
| Graham number | 0.21 | 4.09 | 15.64 | 2.8 | 2.78 | |
| ROIC | 0.04 | -0.07 | -0.03 | -0.03 | -0.15 | |
| Return on tangible assets | -0.02 | -0.4 | -0.36 | 0.05 | -0.14 | |
| Graham Net | -6 | -6.25 | 0.41 | -1.03 | -1.89 | |
| Working capital | 16.35M | 28.17M | 924.46M | 715.98M | 583.24M | |
| Tangible asset value | -160.02M | -179.43M | 122.59M | 497K | -128.55M | |
| Net current asset value | -173.39M | -193.7M | 84.38M | -48.33M | -171.47M | |
| Invested capital | -157.1 | -7.23 | 2.43 | 4.38 | 12.51 | |
| Average receivables | 0 | 23.45M | 37.31M | 64.6M | 73.9M | |
| Average payables | 0 | 16.37M | 23.77M | 29.69M | 37.55M | |
| Average inventory | 0 | 21.32M | 29.23M | 75.85M | 103.88M | |
| Days sales outstanding | 51.96 | 71.06 | 72.17 | 77.59 | 64.22 | |
| Days payables outstanding | 86.57 | 130.02 | 135.48 | 95.83 | 67.28 | |
| Days of inventory on hand | 118.01 | 163.2 | 164.46 | 367.82 | 137.24 | |
| Receivables turnover | 7.02 | 5.14 | 5.06 | 4.7 | 5.68 | |
| Payables turnover | 4.22 | 2.81 | 2.69 | 3.81 | 5.43 | |
| Inventory turnover | 3.09 | 2.24 | 2.22 | 0.99 | 2.66 | |
| ROE | 1.36 | 0.97 | -1.24 | 0.26 | -1.69 | |
| Capex per share | -0.32 | -0.11 | -0.15 | -0.12 | -0.1 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.71 | 0.65 | 0.89 | 0.73 | 0.75 | |
| Net income per share | 0.03 | -0.17 | 0.03 | -0.56 | -0.07 | |
| Operating cash flow per share | -0.04 | -0.1 | 0.17 | 0.14 | -0.04 | |
| Free cash flow per share | -0.06 | -0.13 | 0.14 | 0.11 | -0.06 | |
| Cash per share | 4.11 | 4.02 | 4.14 | 4.21 | 4.06 | |
| Book value per share | 1.24 | 1.11 | 1.22 | 0.68 | 0.46 | |
| Tangible book value per share | 0 | -0.37 | -0.22 | -0.75 | -1 | |
| Share holders equity per share | 1.24 | 1.11 | 1.22 | 0.68 | 0.46 | |
| Interest debt per share | 5.46 | 5.71 | 5.69 | 5.68 | 5.8 | |
| Market cap | 1.26B | 1.67B | 1.11B | 800.04M | 400.31M | |
| Enterprise value | 1.44B | 1.89B | 1.31B | 992.74M | 629.57M | |
| P/E ratio | 82.41 | -18.83 | 82.55 | -2.71 | -10.65 | |
| Price to sales ratio | 12.82 | 19.38 | 9.45 | 8.21 | 4.14 | |
| POCF ratio | -233.19 | -128.55 | 50.57 | 44.59 | -77.43 | |
| PFCF ratio | -153.05 | -94.07 | 59.25 | 53.16 | -54.55 | |
| P/B Ratio | 7.33 | 11.33 | 6.86 | 8.9 | 6.74 | |
| PTB ratio | 7.33 | 11.33 | 6.86 | 8.9 | 6.74 | |
| EV to sales | 14.69 | 21.93 | 11.17 | 10.19 | 6.5 | |
| Enterprise value over EBITDA | 2.72K | -151.41 | -177.42 | -14.08 | -74.95 | |
| EV to operating cash flow | -267.24 | -145.47 | 59.77 | 55.32 | -121.77 | |
| EV to free cash flow | -175.39 | -106.45 | 70.03 | 65.96 | -85.8 | |
| Earnings yield | 0 | -0.01 | 0 | -0.09 | -0.02 | |
| Free cash flow yield | -0.01 | -0.01 | 0.02 | 0.02 | -0.02 | |
| Debt to equity | 4.38 | 5.1 | 4.64 | 8.37 | 12.51 | |
| Debt to assets | 0.75 | 0.76 | 0.75 | 0.77 | 0.8 | |
| Net debt to EBITDA | 346.4 | -17.61 | -27.31 | -2.73 | -27.29 | |
| Current ratio | 10.79 | 10.35 | 9.27 | 5.86 | 6.07 | |
| Interest coverage | -1.52 | -5.09 | -3.85 | -24.15 | -5.38 | |
| Income quality | -1.41 | 0.58 | 4.08 | -0.24 | 0.55 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.29 | 0.35 | 0.3 | 0.38 | 0.3 | |
| Research and developement to revenue | 0.01 | 0.03 | 0.02 | 0.02 | 0.03 | |
| Intangibles to total assets | 0.17 | 0.2 | 0.19 | 0.19 | 0.2 | |
| Capex to operating cash flow | 0.52 | 0.37 | -0.15 | -0.16 | 0.42 | |
| Capex to revenue | -0.03 | -0.06 | -0.03 | -0.03 | -0.02 | |
| Capex to depreciation | -0.5 | -0.84 | -0.33 | -0.39 | -0.22 | |
| Stock based compensation to revenue | 0.08 | 0.04 | 0.07 | 0.08 | 0.02 | |
| Graham number | 0.88 | 2.05 | 0.83 | 2.91 | 0.87 | |
| ROIC | -0.01 | -0.02 | -0.04 | -0.1 | -0.02 | |
| Return on tangible assets | 0 | -0.03 | 0 | -0.09 | -0.01 | |
| Graham Net | -1.1 | -1.51 | -1.37 | -1.77 | -1.93 | |
| Working capital | 715.98M | 676.2M | 685.1M | 612.1M | 583.24M | |
| Tangible asset value | 497K | -48.4M | -29.1M | -99.4M | -128.55M | |
| Net current asset value | -48.33M | -98.8M | -77.7M | -145.2M | -171.47M | |
| Invested capital | 4.38 | 5.1 | 4.64 | 8.37 | 12.51 | |
| Average receivables | 81.23M | 75.09M | 76.3M | 74M | 68.91M | |
| Average payables | 31.46M | 32.32M | 31.85M | 32.65M | 40.33M | |
| Average inventory | 109.07M | 119.27M | 114.55M | 90.95M | 83.11M | |
| Days sales outstanding | 71.33 | 75.5 | 61.43 | 62.65 | 65.11 | |
| Days payables outstanding | 82.83 | 95.87 | 53.35 | 29.37 | 78.85 | |
| Days of inventory on hand | 317.93 | 341.27 | 194.15 | 61.28 | 160.84 | |
| Receivables turnover | 1.26 | 1.19 | 1.47 | 1.44 | 1.38 | |
| Payables turnover | 1.09 | 0.94 | 1.69 | 3.06 | 1.14 | |
| Inventory turnover | 0.28 | 0.26 | 0.46 | 1.47 | 0.56 | |
| ROE | 0.02 | -0.15 | 0.02 | -0.82 | -0.16 | |
| Capex per share | -0.02 | -0.04 | -0.02 | -0.02 | -0.02 |
SKIN Frequently Asked Questions
What is The Beauty Health Company stock symbol ?
The Beauty Health Company is a US stock , located in Long beach of Ca and trading under the symbol SKIN
What is The Beauty Health Company stock quote today ?
The Beauty Health Company stock price is $3.255 today.
Is The Beauty Health Company stock public?
Yes, The Beauty Health Company is a publicly traded company.
Company Profile
- Volume Average 2.7M
- Market Capitalization 451.74M
- Employee 881
- CEO Ms. Marla Malcolm Beck
- Headquarters Long Beach,CA,US
- IPO Date 2020-11-24
-
Website
https://www.beautyhealth.com 
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
